Hemolytic Characteristics of a Pivot Bearing Supported Gyro Centrifugal Pump (C1E3) Simulating Various Clinical Applications

Takami, Yoshiyuki; Makinouchi, Kenzo; Nakazawa, Tadashi; Benkowski, Robert; Glueck, Julie; Ohara, Yasuhisa; Nosé, Yukihiko

doi:10.1111/j.1525-1594.1996.tb04592.x

Cited by 47 publications

(39 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As for the atraumatic aspects of operation, this pump showed a normalized index of hemolysis (NIH) of 0.007 ? 0.001 in a CPB condition of 5 Wmin against 325 mm Hg while the NIH of the BP-80 was 0.018+0.002 under the same pumping conditions (6).…”

Section: C1e3 Pumpmentioning

confidence: 99%

Comparison of the Gyro C1E3 and BioMedicus Centrifugal Pump Performances During Cardiopulmonary Bypass

et al. 1997

Self Cite

View full text Add to dashboard Cite

The compact eccentric inlet port (C1E3) centrifugal blood pump was developed as a cardiopulmonary bypass (CPB) pump. The C1E3 pump incorporated a sealless design with a blood stagnation free structure. The pump impeller was magnetically coupled to the driver magnet in a sealless manner. To develop an atraumatic and antithrombogenic centrifugal pump without a shaft seal junction, a double pivot bearing system was introduced. Recently, a mass production model of the C1E3 was fabricated and evaluated. The ratio of the normalized index of hemolysis (NIH) of the C1E3 was 0.007 g/ 100 L, in comparison to the NIH of the BP-80, 0.018 g/ 100 L, each in a CPB condition of 5 L/min against 325 mm Hg. Both pumps were compared in identical in vitro circuits. To further evaluate the pumps during cardiopulmonary bypass for reliability and function, 6 h of CPB was performed on each of 8 bovines using either the C1E3 or BP-80 centrifugal pump. The BP-80 and C1E3 provided pump flows of 50-60 ml/kg/min without incident. The hemodynamics were stable, and the hematology and biochemistry data were within normal ranges. There were no statistically significant differences between the 2 groups. Concerning the plasma free hemoglobin values, a mass production model of the C1E3 pump had the same hemolysis levels as the BP-80. Our preliminary studies reveal that the C1E3 pump is reliable. Also, the C1E3 will satisfy clinical requirements as a cardiopulmonary bypass pump.

show abstract

Section: C1e3 Pumpmentioning

confidence: 99%

Comparison of the Gyro C1E3 and BioMedicus Centrifugal Pump Performances During Cardiopulmonary Bypass

et al. 1997

Self Cite

View full text Add to dashboard Cite

show abstract

“…are associated with intravascular hemolysis, and consequently there is the potential risk for the development of pulmonary hypertension, such as schistosomiasis (3,4), and iatrogenic hemolysis from mechanical heart valves (5, 6), left ventricular assist devices, and cardiopulmonary bypass procedures (7)(8)(9)(10)(11). Importantly, there are no case reports of pulmonary hypertension complicating iron deficiency anemia, the most common anemia in the world, suggesting a requirement for intravascular hemolysis for the development of this complication.…”

Section: What This Study Adds To the Fieldmentioning

confidence: 99%

Hemodynamic and Functional Assessment of Patients with Sickle Cell Disease and Pulmonary Hypertension

Anthi¹,

Machado²,

Jison³

et al. 2007

Am J Respir Crit Care Med

233

231

View full text Add to dashboard Cite

Rationale: Although pulmonary hypertension (PH) is a common complication of sickle cell disease (SCD) associated with high mortality, there exist few data characterizing hemodynamics and cardiopulmonary function in this population. Objectives: To characterize hemodynamics and cardiopulmonary function in patients with SCD with and without PH. Methods: Patients with SCD with PH (n ϭ 26) were compared with control subjects with SCD but without PH (n ϭ 17), matched for age, hemoglobin levels, and fetal hemoglobin levels. Measurements and Main Results: Upon catheterization, 54% of the patients with PH had pulmonary arterial hypertension, and 46% had pulmonary venous hypertension. When compared with control subjects, patients with PH exhibited lower six-minute-walk distance (435 Ϯ 31 vs. 320 Ϯ 20 m, p ϭ 0.002) and oxygen consumption (50 Ϯ 3% vs. 41 Ϯ 2% of predicted, p ϭ 0.02), and also had mild restrictive lung disease and more perfusion abnormalities on radionuclide lung scans. The six-minute-walk distance in this population inversely correlated with tricuspid regurgitant jet velocity (r ϭ Ϫ0.55, p Ͻ 0.001), and mean pulmonary artery pressure (r ϭ Ϫ0.57, p Ͻ 0.001), and directly correlated with maximal oxygen consumption (r ϭ 0.49, p ϭ 0.004), even after adjustment for hemoglobin, supporting an independent contribution of increasing pulmonary artery pressures to loss of exercise capacity. Conclusions: Patients with SCD-associated PH have both pulmonary arterial and venous PH associated with severe limitations in exercise capacity, likely compounded by interstitial lung fibrosis and severe anemia. These data support the use of the six-minute-walk distance as an index of PH and cardiopulmonary function in patients with SCD.Keywords: sickle cell disease; pulmonary hypertension; six-minute walk; hemodynamics; echocardiogram Pulmonary arterial hypertension is an increasingly recognized complication of chronic hereditary and acquired hemolytic anemias, including sickle cell disease (SCD), thalassemia intermedia and major, paroxysmal nocturnal hemoglobinuria, hereditary spherocytosis and stomatocytosis, microangiopathic hemolytic anemias, pyruvate kinase deficiency, alloimmune hemolytic anemia, and possibly malaria (1, 2). In addition, certain conditions AT A GLANCE COMMENTARY Scientific Knowledge on the SubjectPulmonary hypertension is an emerging complication of sickle cell disease with high mortality. There are few data characterizing hemodynamics and cardiopulmonary function in this population. What This Study Adds to the FieldPatients with sickle cell disease-associated pulmonary hypertension have both pulmonary arterial and venous pulmonary hypertension associated with severe limitations in exercise capacity, likely compounded by interstitial lung fibrosis and severe anemia.are associated with intravascular hemolysis, and consequently there is the potential risk for the development of pulmonary hypertension, such as schistosomiasis (3, 4), and iatrogenic hemolysis from mechanical heart valves (5, 6), left ventricula...

show abstract

“…15 We also demonstrated that less haemolytic characteristics of the Gyro pump than the BP-80 depends upon less pump power loss against the increase in total pressure head and rotational pump speed. With the BP-80, when the pressure and/or pump speed are increased, more pump power is lost, and the lost power would be energetically changed to heat, causing more damage to erythrocytes.…”

Section: Evaluation Of the Kyocera Gyro Centrifugal Blood Pump 339mentioning

confidence: 88%

Preclinical evaluation of the Kyocera Gyro centrifugal blood pump for cardiopulmonary bypass

et al. 1997

Self Cite

View full text Add to dashboard Cite

The Kyocera Gyro pump has been developed as a completely seal-less centrifugal pump to overcome the problems of the conventional centrifugal pumps. The Gyro pump is a double pivot bearing-supported centrifugal pump with several specific design features, including its eccentric inlet port. We investigated the feasibility of the Gyro pump for cardiopulmonary bypass (CPB) in a bovine model, comparing it with the BioMedicus pump (BP-80). Ten healthy calves (5: Gyro pump, 5: BP-80) underwent 6 h of mildly hypothermic CPB at approximately 33 degrees C. Both pumps provided more than 50 ml/kg/min without any incidents. The haemodynamics of both groups remained stable within the normal range. All haematology and biochemistry data demonstrated no significant differences between the two groups. However, values of plasma-free haemoglobin and lactate dehydrogenase were less throughout the experiments of the Gyro pump than those of the BP-80. To obtain flow equivalent to that of the BP-80, the Gyro pump needed less rotational speeds than the BP-80 (2749.7 +/- 233.3 versus 3170.6 +/- 300.8 rpm. p < 0.05). Less rotational speed in addition to the difference in operating principle may contribute to less blood damage during the CPB OF the Gyro pump. After pumping for CPB, no leakage or thrombus formation was observed in either pump. The present study indicated that the Kyocera Gyro pump can be applied as a centrifugal pump for CPB with the same performance as the BP-80 and with relatively less haemolysis than the BP-80.

show abstract

Hemolytic Characteristics of a Pivot Bearing Supported Gyro Centrifugal Pump (C1E3) Simulating Various Clinical Applications

Cited by 47 publications

References 14 publications

Comparison of the Gyro C1E3 and BioMedicus Centrifugal Pump Performances During Cardiopulmonary Bypass

Comparison of the Gyro C1E3 and BioMedicus Centrifugal Pump Performances During Cardiopulmonary Bypass

Hemodynamic and Functional Assessment of Patients with Sickle Cell Disease and Pulmonary Hypertension

Preclinical evaluation of the Kyocera Gyro centrifugal blood pump for cardiopulmonary bypass

Contact Info

Product

Resources

About